2,500 Shares in Ligand Pharmaceuticals Inc. (LGND) Purchased by Barbara Oil Co.

Barbara Oil Co. acquired a new position in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) in the fourth quarter, Holdings Channel reports. The firm acquired 2,500 shares of the biotechnology company’s stock, valued at approximately $342,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in LGND. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Ligand Pharmaceuticals by 48.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,101 shares of the biotechnology company’s stock worth $151,000 after acquiring an additional 359 shares during the last quarter. Harbor Advisors LLC purchased a new position in Ligand Pharmaceuticals in the 3rd quarter worth approximately $204,000. Round Table Services LLC purchased a new position in Ligand Pharmaceuticals in the 3rd quarter worth approximately $205,000. Ameritas Investment Partners Inc. raised its holdings in Ligand Pharmaceuticals by 9.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,799 shares of the biotechnology company’s stock worth $218,000 after acquiring an additional 154 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new position in Ligand Pharmaceuticals in the 3rd quarter worth approximately $230,000.

In other Ligand Pharmaceuticals news, Director Stephen L. Sabba sold 925 shares of the business’s stock in a transaction on Wednesday, December 20th. The shares were sold at an average price of $137.25, for a total transaction of $126,956.25. Following the completion of the sale, the director now directly owns 26,985 shares in the company, valued at approximately $3,703,691.25. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director John W. Kozarich sold 2,500 shares of the business’s stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $145.00, for a total transaction of $362,500.00. Following the sale, the director now owns 33,149 shares of the company’s stock, valued at $4,806,605. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 63,024 shares of company stock valued at $9,934,043. Company insiders own 8.30% of the company’s stock.

Shares of Ligand Pharmaceuticals Inc. (LGND) opened at $157.14 on Friday. The firm has a market cap of $3,317.36, a price-to-earnings ratio of 227.74, a price-to-earnings-growth ratio of 1.68 and a beta of 1.07. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.95 and a current ratio of 0.97. Ligand Pharmaceuticals Inc. has a 12 month low of $95.08 and a 12 month high of $170.30.

LGND has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $170.00 target price on shares of Ligand Pharmaceuticals in a research note on Friday, February 2nd. Zacks Investment Research lowered shares of Ligand Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, November 30th. Roth Capital set a $158.00 target price on shares of Ligand Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, November 13th. Craig Hallum reiterated a “buy” rating and set a $170.00 target price (up from $160.00) on shares of Ligand Pharmaceuticals in a research note on Wednesday, November 15th. Finally, BidaskClub upgraded shares of Ligand Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 5th. Two research analysts have rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $150.83.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://ledgergazette.com/2018/02/18/2500-shares-in-ligand-pharmaceuticals-inc-lgnd-purchased-by-barbara-oil-co.html.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.

Want to see what other hedge funds are holding LGND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ligand Pharmaceuticals Inc. (NASDAQ:LGND).

Institutional Ownership by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply